Haanen JBAG - Search Results

1

OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.

van der Sluis TC, Beyrend G, van der Gracht ETI, Abdelaal T, Jochems SP, Belderbos RA, Wesselink TH, van Duikeren S, van Haften FJ, Redeker A, Ouboter LF, Beyranvand Nejad E, Camps M, Franken KLMC, Linssen MM, Hohenstein P, de Miranda NFCC, Mei H, Bins AD, Haanen JBAG, Aerts JG, Ossendorp F, Arens R. van der Sluis TC, et al. Among authors: haanen jbag. Cell Rep Med. 2023 Mar 21;4(3):100939. doi: 10.1016/j.xcrm.2023.100939. Epub 2023 Feb 15. Cell Rep Med. 2023. PMID: 36796366 Free PMC article.

2

On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients.

van Oijen M, Bins A, Elias S, Sein J, Weder P, de Gast G, Mallo H, Gallee M, Van Tinteren H, Schumacher T, Haanen J. van Oijen M, et al. Clin Cancer Res. 2004 Jul 15;10(14):4754-60. doi: 10.1158/1078-0432.CCR-04-0260. Clin Cancer Res. 2004. PMID: 15269149

3

A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression.

Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TN, Haanen JB. Bins AD, et al. Nat Med. 2005 Aug;11(8):899-904. doi: 10.1038/nm1264. Epub 2005 Jun 19. Nat Med. 2005. PMID: 15965482 Free article.

4

Design and use of conditional MHC class I ligands.

Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, van de Kasteele W, Rimmelzwaan GF, Haanen JB, Ovaa H, Schumacher TN. Toebes M, et al. Nat Med. 2006 Feb;12(2):246-51. doi: 10.1038/nm1360. Epub 2006 Feb 5. Nat Med. 2006. PMID: 16462803

5

Intravital imaging of fluorescent markers and FRET probes by DNA tattooing.

Bins AD, van Rheenen J, Jalink K, Halstead JR, Divecha N, Spencer DM, Haanen JB, Schumacher TN. Bins AD, et al. BMC Biotechnol. 2007 Jan 3;7:2. doi: 10.1186/1472-6750-7-2. BMC Biotechnol. 2007. PMID: 17201912 Free PMC article.

6

Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.

Bins A, Mallo H, Sein J, van den Bogaard C, Nooijen W, Vyth-Dreese F, Nuijen B, de Gast GC, Haanen JB. Bins A, et al. J Immunother. 2007 Feb-Mar;30(2):234-9. doi: 10.1097/01.cji.0000211333.06762.47. J Immunother. 2007. PMID: 17471170 Clinical Trial.

7

In vivo antigen stability affects DNA vaccine immunogenicity.

Bins AD, Wolkers MC, van den Boom MD, Haanen JB, Schumacher TN. Bins AD, et al. J Immunol. 2007 Aug 15;179(4):2126-33. doi: 10.4049/jimmunol.179.4.2126. J Immunol. 2007. PMID: 17675471

8

Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.

Jorritsma A, Bins AD, Schumacher TN, Haanen JB. Jorritsma A, et al. Cancer Res. 2008 Apr 1;68(7):2455-62. doi: 10.1158/0008-5472.CAN-07-5254. Cancer Res. 2008. PMID: 18381454

9

Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates.

Verstrepen BE, Bins AD, Rollier CS, Mooij P, Koopman G, Sheppard NC, Sattentau Q, Wagner R, Wolf H, Schumacher TN, Heeney JL, Haanen JB. Verstrepen BE, et al. Vaccine. 2008 Jun 19;26(26):3346-51. doi: 10.1016/j.vaccine.2008.03.091. Epub 2008 Apr 21. Vaccine. 2008. PMID: 18467010

10

Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen.

Bos R, van Duikeren S, Morreau H, Franken K, Schumacher TN, Haanen JB, van der Burg SH, Melief CJ, Offringa R. Bos R, et al. Cancer Res. 2008 Oct 15;68(20):8446-55. doi: 10.1158/0008-5472.CAN-08-1864. Cancer Res. 2008. PMID: 18922918

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

332 results

Search Page